Biohaven Ltd., a clinical-stage biopharmaceutical company, reported significant progress in its pipeline during Q1 2026, maintaining a strong liquidity position with $273 million in cash and equivalents. The company's revenue model hinges on the future commercialization of its lead candidate, troriluzole, with milestone-driven funding from a senior secured Note Purchase Agreement that aligns investor returns with product sales. Despite encouraging developments, Biohaven remains exposed to typical clinical-stage risks including regulatory approvals, clinical trial outcomes, and financial covenants tied to its note agreements. Growth drivers center on late-stage clinical advancement and potential regulatory milestones, while watchpoints include capitalization of the contingent second tranche funding and successful commercialization preparations.